Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,856 active trials61 approved drugs307 evidence items
- NCIt
- C156482
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,398 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02009579 | ENGOT-cx1/BGOG-cx1: 3 Weekly Carboplatin/Paclitaxel With or Without Nintedanib in Cervix Cancer | completed | Phase 2 | 120 | Belgian Gynaecological Oncology GroupOTHER | 4 | Aug 7, 2024 | clinicaltrials |
| NCT01685268 | A Study of HSP90 Inhibitor AT13387 Alone or in Combination With Abiraterone Acetate | completed | Phase 1 / Phase 2 | 49 | Astex Pharmaceuticals, Inc.INDUSTRY | 4 | Aug 2, 2024 | clinicaltrials |
| NCT03336983 | Luteinizing Hormone-releasing Hormone Analogue and Enzalutamide +/- Zoledronic Acid in Prostate Cancer Patients(BonEnza) | completed | Phase 2 | 126 | Azienda Socio Sanitaria Territoriale degli Spedali Civili di BresciaOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT03339635 | Short-term Testosterone Replacement in Testicular Cancer Survivors | completed | Phase 2 | 32 | University Medical Center GroningenOTHER | 1 | Jul 30, 2024 | clinicaltrials |
| NCT03513952 | Atezolizumab and CYT107 in Treating Participants With Locally Advanced, Inoperable, or Metastatic Urothelial Carcinoma | completed | Phase 2 | 47 | National Cancer Institute (NCI)NIH | 1 | Jul 26, 2024 | clinicaltrials |
| NCT03602586 | Testing Whether the Combination of Two Immunotherapy Drugs Have Activity in Recurrent or Persistent Clear Cell Ovarian Cancer | completed | Phase 2 | 14 | National Cancer Institute (NCI)NIH | 2 | Jul 26, 2024 | clinicaltrials |
| NCT02923934 | A Phase II Trial of Ipilimumab and Nivolumab for the Treatment of Rare Cancers | completed | Phase 2 | 120 | Olivia Newton-John Cancer Research InstituteOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT04693507 | Teverelix Evaluated in Advanced Prostate Cancer(TEACh) | completed | Phase 2 | 50 | Antev Ltd.INDUSTRY | 1 | Jul 23, 2024 | clinicaltrials |
| NCT04570839 | COM701 in Combination With BMS-986207 and Nivolumab in Subjects With Advanced Solid Tumors. | completed | Phase 1 / Phase 2 | 48 | Compugen LtdINDUSTRY | 1 | Jul 18, 2024 | clinicaltrials |
| NCT03759600 | Japan Phase 2 Study of Niraparib in Participants With Advanced, Relapsed Ovarian Cancer | completed | Phase 2 | 20 | TakedaINDUSTRY | 1 | Jul 16, 2024 | clinicaltrials |
| NCT03989336 | A Study of the Pan-immunotherapy in Patients With Relapsed/Refractory Ovarian Cancer | completed | Phase 2 | 84 | Chinese PLA General HospitalOTHER | 1 | Jul 15, 2024 | clinicaltrials |
| NCT03389451 | 68Ga PSMA PET for Patients With Biochemical Recurrence of Prostate Cancer | completed | Phase 2 / Phase 3 | 30 | Michael Graham PhD, MDOTHER | 1 | Jul 12, 2024 | clinicaltrials |
| NCT01446731 | Dendritic Cell Vaccination and Docetaxel for Patients With Prostate Cancer | completed | Phase 2 | 43 | Inge Marie SvaneOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT03557918 | Trial of Tremelimumab in Patients With Previously Treated Metastatic Urothelial Cancer | completed | Phase 2 | 26 | Matthew GalskyOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT03558087 | Gemcitabine, Cisplatin, Plus Nivolumab in Patients With Muscle-invasive Bladder Cancer With Selective Bladder Sparing | completed | Phase 2 | 76 | Matthew GalskyOTHER | 1 | Jun 27, 2024 | clinicaltrials |
| NCT01326871 | A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial Cancer | completed | Phase 1 / Phase 2 | 68 | Altor BioScienceINDUSTRY | 1 | Jun 25, 2024 | clinicaltrials |
| NCT03319745 | Pembrolizumab in Treating Patients With Bladder Cancer Undergoing Radical Cystectomy | completed | Phase 2 | 23 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT04408924 | Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer(CYCLONE 1) | completed | Phase 2 | 44 | Eli Lilly and CompanyINDUSTRY | 3 | Jun 25, 2024 | clinicaltrials |
| NCT04799639 | Efficacy and Toxicity of Paclitaxel, Cisplatin Combined With Sindilimab in NACT for Locally Advanced Cervical Cancer | completed | Phase 2 | 47 | Sun Yat-sen UniversityOTHER | 1 | Jun 25, 2024 | clinicaltrials |
| NCT04525131 | Safety, Dose Tolerance, Pharmacokinetics, Pharmacodynamics of CPX-POM in Patients With Newly Diagnosed or Recurrent Bladder Tumors | completed | Phase 2 | 12 | CicloMed LLCINDUSTRY | 1 | Jun 18, 2024 | clinicaltrials |
| NCT03759587 | Japan Phase 2 Study of Niraparib (Maintenance Therapy) in Participants With Relapsed Ovarian Cancer | completed | Phase 2 | 19 | TakedaINDUSTRY | 1 | Jun 7, 2024 | clinicaltrials |
| NCT00194714 | Vaccine Therapy in Treating Patients With Stage IV HLA-A2 and HER2 Positive Breast or Ovarian Cancer Receiving Trastuzumab | completed | Phase 1 / Phase 2 | 22 | University of WashingtonOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT01194271 | Neoadjuvant Ipilimumab in Prostate Cancer | completed | Phase 2 | 19 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT05141760 | 18F-PSMA PET and MRI in the Primary Staging of Prostate Cancer Patients | completed | Phase 2 | 150 | University of AlbertaOTHER | 1 | Jun 6, 2024 | clinicaltrials |
| NCT02933255 | PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer | completed | Phase 1 / Phase 2 | 24 | National Cancer Institute (NCI)NIH | 1 | May 31, 2024 | clinicaltrials |
| NCT02453009 | Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer(CHEIRON) | completed | Phase 2 | 246 | Santa Chiara HospitalOTHER | 1 | May 30, 2024 | clinicaltrials |
| NCT04205630 | SYD985 in Patients With HER2-expressing Recurrent, Advanced or Metastatic Endometrial Carcinoma | completed | Phase 2 | 64 | Byondis B.V.INDUSTRY | 7 | May 30, 2024 | clinicaltrials |
| NCT03126812 | Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer | completed | Phase 1 / Phase 2 | 33 | The Netherlands Cancer InstituteOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT05679193 | Perioperative Propranolol During Prostatectomy to Decrease Cancer Recurrence(PeP-RALP) | completed | Phase 2 | 40 | Oslo University HospitalOTHER | 1 | May 29, 2024 | clinicaltrials |
| NCT03926936 | FUlvestrant in Gynecological Cancers That Are Potentially Hormone Sensitive: the FUCHSia Study(FUCHSia) | completed | Phase 2 | 17 | Frederic AmantOTHER | 2 | May 28, 2024 | clinicaltrials |
| NCT03093155 | Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab | completed | Phase 2 | 78 | Yale UniversityOTHER | 1 | May 14, 2024 | clinicaltrials |
| NCT04823065 | 4FMFES-PET Imaging of Endometrial and Ovarian Cancers | completed | Phase 1 / Phase 2 | 53 | Centre de recherche du Centre hospitalier universitaire de SherbrookeOTHER | 1 | May 13, 2024 | clinicaltrials |
| NCT01439490 | FES-PET to Determine ER-expression in Epithelial Ovarian Cancer | completed | Phase 2 | 15 | University Medical Center GroningenOTHER | 1 | May 6, 2024 | clinicaltrials |
| NCT02864147 | Treatment of High-Grade Pre-Neoplastic Cervical Lesions (CIN 2/3) | completed | Phase 2 | 134 | Yale UniversityOTHER | 1 | May 2, 2024 | clinicaltrials |
| NCT03572387 | A Pilot Study of 5-AZA and ATRA for Prostate Cancer With PSA-only Recurrence After Local Treatment | completed | Phase 2 | 14 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Apr 30, 2024 | clinicaltrials |
| NCT03097328 | Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma | completed | Phase 2 | 39 | Bradley A. McGregor, MDOTHER | 1 | Apr 29, 2024 | clinicaltrials |
| NCT04742959 | Study of TT-00420 (Tinengotinib) Tablet as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 203 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Apr 26, 2024 | clinicaltrials |
| NCT01088347 | Mapatumumab, Cisplatin and Radiotherapy for Advanced Cervical Cancer | completed | Phase 1 / Phase 2 | 9 | University Medical Center GroningenOTHER | 1 | Apr 19, 2024 | clinicaltrials |
| NCT04028388 | ModraDoc006/r vs Docetaxel IV in Metastatic Prostate Cancer | completed | Phase 2 | 135 | Modra PharmaceuticalsINDUSTRY | 6 | Apr 17, 2024 | clinicaltrials |
| NCT04089553 | An Open-label, Phase II Study of AZD4635 in Patients With Prostate Cancer | completed | Phase 2 | 59 | AstraZenecaINDUSTRY | 1 | Apr 16, 2024 | clinicaltrials |
| NCT03148795 | A Study of Talazoparib in Men With DNA Repair Defects and Metastatic Castration-Resistant Prostate Cancer | completed | Phase 2 | 128 | PfizerINDUSTRY | 14 | Apr 5, 2024 | clinicaltrials |
| NCT00445965 | Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer | completed | Phase 2 | 78 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Apr 4, 2024 | clinicaltrials |
| NCT02325557 | ADXS31-142 Alone and in Combination With Pembrolizumab (MK-3475) in Participants With Previously Treated Metastatic Castration-Resistant Prostate Cancer (mCRPC) | completed | Phase 1 / Phase 2 | 50 | Advaxis, Inc.INDUSTRY | 1 | Apr 2, 2024 | clinicaltrials |
| NCT02108652 | A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 2) | completed | Phase 2 | 310 | Hoffmann-La RocheINDUSTRY | 8 | Mar 28, 2024 | clinicaltrials |
| NCT02951767 | A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1) | completed | Phase 2 | 119 | Hoffmann-La RocheINDUSTRY | 8 | Mar 28, 2024 | clinicaltrials |
| NCT03311555 | A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR) | completed | Phase 2 | 39 | Andrew J. Armstrong, MDOTHER | 1 | Mar 19, 2024 | clinicaltrials |
| NCT01759771 | Vitamin D3 Supplementation for Low-Risk Prostate Cancer: A Randomized Trial(VD3PCa) | completed | Phase 2 | 130 | VA Office of Research and DevelopmentFED | 1 | Mar 18, 2024 | clinicaltrials |
| NCT03126331 | Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab | completed | Phase 2 | 26 | Case Comprehensive Cancer CenterOTHER | 1 | Mar 18, 2024 | clinicaltrials |
Data updated 24 days agoSource updated Aug 7, 2024source: clinicaltrials